brain cancers
cancer stem cells
clinical studies
Olig2
median survival
Gliomas
Pre-clinical results
survival rates
conventional cancer drugs
year survival rate
identification of clinical partners
treatment of glioblastoma
tumour bulk
tumour expansion
tumour progression
primary malignant brain tumours
blood-brain barrier
Phase
Europe
Curtanaâ€™s small molecule compound
Patented small molecule therapeutics
early studies
Conventional therapies
selected tumours
median improvement
Standard of care treatment
high therapeutic index relative
little hope
patients
tumorigenesis
multi-centre trials
potent radiosensitiser
transcription factor
accounting
lung
people
months
central nervous system
novel approach
diagnoses
drug marketing approval
biggest killer
feasibility
cure
project
benefit
potential investors
answer